CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(03): 312-316
DOI: 10.1055/s-0042-1742634
Original Article

Clinical and Microbiological Profile of Patients with Bloodstream Infections Caused by Burkholderia cepacia Complex

Tasneem Siddiqui
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Chinmoy Sahu
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Sangram Singh Patel
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Ujjala Ghoshal
1   Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
› Author Affiliations


IntroductionBurkholderia cepacia complex (BCC) is an emerging pathogen causing nosocomial bloodstream infections (BSIs), and its treatment is challenging due to its multidrug resistance. In India, there is a dearth of data on BSIs caused by BCC, therefore, an updated study is required to know the clinical and microbiological profile of these patients. We aimed to study the clinical epidemiology and antibiotic susceptibility pattern of BCC isolated from blood samples in our hospital.

Materials and Methods This observational study was conducted from January 2019 to December 2020 at a tertiary care center in northern India. All the blood cultures were done on an automated blood culture system. All BCC isolates of BSI were identified depending on their morphological properties and biochemical reactions, and underwent the matrix-assisted laser desorption ionization time-of-flight mass spectrometry system to confirm diagnosis. Antibiotic susceptibility testing was done as per Clinical Laboratory and Standards Institute guidelines.

Results BCC was isolated from 30 BSI patients over a 2-year period. Sixty-six percent (20/30) of patients had cancer and a majority of them were undergoing chemotherapy. The most common predisposing factors were the use of steroids, immunosuppressive drugs, and chemotherapy (93.3%), central lines (83.3%), use of higher antibiotics (60%), and diabetes mellitus type 2 (60%). The most common species isolated were B. cepacia (64%) and B. cenocepacia (30%). Isolates showed highest sensitivity to minocycline (100%), ceftazidime (73.3%), and meropenem (70%) and the least to ticarcillin–clavulanate.

Conclusion BCC is an emerging pathogen causing BSIs, especially in malignancy patients. Minocycline can be a good choice for these bacteria.

Publication History

Article published online:
09 February 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Mahenthiralingam E, Vandamme P, Campbell ME. et al. Infection with BCC genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Bukholderia multivorans. Clin Infect Dis 2001; 33: 1469-1475
  • 2 Siddiqui AH, Mulligan ME, Mahenthiralingam E. et al. An episodic outbreak of genetically related Burkholderia cepacia among non-cystic fibrosis patients at a university hospital. Infect Control Hosp Epidemiol 2001; 22 (07) 419-422
  • 3 Estivariz CF, Bhatti LI, Pati R. et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006; 130 (05) 1346-1353
  • 4 Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004; 25 (03) 231-239
  • 5 LiPuma JJ CB, Lum GD, Vandamme PAR. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas and Acidovorax. In: Murray PR BE, Jorgensen JH, Landry ML, Pfaller MA. eds. Manual of Clinical Microbiology. Washington, DC: ASM Press; 2007: 749-769
  • 6 Gautam V, Arora A, Madhup SK. et al. Burkholderia cepacia complex in septicaemic non-cystic fibrosis cases from two tertiary care hospitals in north India. Indian J Med Res 2010; 131: 829-832
  • 7 Gautam V, Ray P, Das A. et al. Two cases of Burkholderia cenocepacia in septicemic patients. Jpn J Infect Dis 2008; 61 (02) 133-134
  • 8 Gautam V, Ray P, Puri GD. et al. Investigation of Burkholderia cepacia complex in septicaemic patients in a tertiary care hospital, India. Nepal Med Coll J 2009; 11 (04) 222-224
  • 9 Gautam V, Ray P, Vandamme P. et al. Identification of lysine positive non-fermenting gram negative bacilli (Stenotrophomonas maltophilia and Burkholderia cepacia complex). Indian J Med Microbiol 2009; 27 (02) 128-133
  • 10 Mukhopadhyay C, Bhargava A, Ayyagari A. Two novel clinical presentations of Burkholderia cepacia infection. J Clin Microbiol 2004; 42 (08) 3904-3905
  • 11 Winn Jr W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P. et al. Nonfermenting gram negative bacilli. In: Koneman's Color Atlas and Textbook of Diagnostic Microbiology. 6th edition.. USA: Lippincott Williams and Wilkins Company; 2006: 305-391
  • 12 Ling TKW, Tam PC, Liu ZK, Cheng AFB. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates. J Clin Microbiol 2001; 39 (08) 2964-2966
  • 13 Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M-100. 29th edition.. Wayne, PA: CLSI; 2019
  • 14 Ku NS, Han SH, Kim CO. et al. Risk factors for mortality in patients with Burkholderia cepacia complex bacteraemia. Scand J Infect Dis 2011; 43 (10) 792-797
  • 15 Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005; 3 (02) 144-156
  • 16 Reik R, Spilker T, Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005; 43 (06) 2926-2928
  • 17 Bressler AM, Kaye KS, LiPuma JJ. et al. Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fibrosis: a case-control study. Infect Control Hosp Epidemiol 2007; 28 (08) 951-958
  • 18 Burns JL, Wadsworth CD, Barry JJ, Goodall CP. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 1996; 40 (02) 307-313
  • 19 Aronoff SC. Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother 1988; 32 (11) 1636-1639
  • 20 Trépanier S, Prince A, Huletsky A. Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother 1997; 41 (11) 2399-2405
  • 21 Kady HE, Mohamed ONE, Abaza AF, Zidan YHM. Burkholderia cepacia complex among intensive care unit patients in two private hospitals in Alexandria. Inter J Sci Technol Research 2018; 7 (01) 102-109
  • 22 Omar N, El Raouf HA, Okasha H, Nabil N. Microbiological assessment of Burkholderia cepacia complex (BCC) isolates in Alexandria Main University Hospital. Alex J Med 2015; 51 (01) 41-46